Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Multiple Sclerosis: Clinical Subtypes

Progressive Disease: Overlapping Subtypes?

Radiologically Isolated Syndrome and Risk of MS

Proportion of Patients With SPMS and Other MS Phenotypes

Need to Detect Disease Activity and Disease Progression: Criteria for Progressive MS Phenotypes

Diagnosing SPMS: Input From Patients

Age of Onset of SPMS

Two Components of SMPS as Targets for Treatment

Long-Term Follow-Up on DMT Use: Conversion to SPMS

Recent RCTs in SPMS: Negative for Primary Endpoints

Recent RCTs in SPMS: Positive for Primary Endpoints

Understanding the Pathophysiology of Progressive MS: Potential Treatment Targets

Phase 3 Study of Siponimod: Reduced Risk of Disability Progression

Subgroup Analyses of Phase 3 Study of Siponimod: Risk of Disability Progression at 6 Months

Siponimod in SPMS Shows Distinct Results From Fingolimod in PPMS

S1P Receptor Gene Expression

Randomized, Double-Blind, Placebo-Controlled Study of Biotin in PPMS and SPMS

Extension Phase Results With Biotin: Improvement After Switch From Placebo

Phase 2 Results for High-Dose Simvastatin and Brain Atrophy Reduction in SPMS: MS-STAT

Effect of High-Dose Simvastatin on Cognitive Measures: MS-STAT Cognitive Substudy

Analysis of the Potential Effect of Lipid-Lowering on Disability Reduction With Simvastatin

Phase 2 Study of Ibudilast in PPMS and SPMS

Main Safety Findings With Ibudilast

Ibudilast: Background and Mechanism of Action

MS-SMART: Multiarm Trial Design

PPMS and SPMS as One Entity in Clinical Trials? Clinician Perspectives

Concluding Remarks I

Concluding Remarks II

Abbreviations

Abbreviations (cont)